Beijing Iman Biotechnology

Yiman Biotech is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative targeted radiopharmaceuticals for oncology. The company utilizes a theranostic approach, combining diagnostic imaging with targeted radionuclide therapy to provide precision treatment for various solid tumors. Their proprietary technology platform focuses on the design of high-affinity ligands, such as small molecules and peptides, conjugated with therapeutic or diagnostic radioisotopes. Yiman Biotech's lead programs target well-validated markers including Fibroblast Activation Protein (FAP) and Prostate-Specific Membrane Antigen (PSMA). The company is backed by prominent investors such as Sequoia China and Hillhouse Capital, aiming to advance the field of nuclear medicine through integrated R&D and manufacturing capabilities.